Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...
The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...
Among survivors of non-small cell lung cancer, nearly 8% developed non-lung secondary cancers over about 6 years, and this ...
Wendy Brooks, a patient with extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, sat down ...
SCLC treatment has advanced significantly, and you will not face this journey alone. You have a dedicated medical team ready ...
Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers of Brevard and an assistant professor at the ...
4d
US approves oral drug for adults with rare type of lung cancer after early clinical trials globally
Sevabertinib showed promise in early trials for non-squamous non-small-cell lung cancer with HER2 mutations. Read more at ...
The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...
The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...
“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback